{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-034564","form_type":"8-K","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2026-02-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.867346+00:00","generated_at":"2026-05-16T05:21:01.746685+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"FDA clears IND for Prelude's JAK2V617F inhibitor PRT12396; Phase 1 to start by Q2 2026","bullets":["FDA cleared IND for PRT12396, a mutant-selective JAK2V617F inhibitor for myeloproliferative neoplasms.","Phase 1 study in polycythemia vera and myelofibrosis to initiate by Q2 2026.","PRT12396 is subject to an exclusive option agreement with Incyte (announced Nov 2025).","JAK2V617F mutation drives ~95% of PV, 60% of ET, and 55% of MF cases.","Open-label Phase 1 will assess safety, efficacy, and PK profile."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-034564","json":"https://secwatch.observer/filing/0001193125-26-034564.json","markdown":"https://secwatch.observer/filing/0001193125-26-034564.md","text":"https://secwatch.observer/filing/0001193125-26-034564.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000119312526034564/0001193125-26-034564-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000119312526034564/prld-20260129.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T05:21:01.746685+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}